Japan Drug Cost Concerns Rise To The Top
Executive Summary
Sharply rising medical spending in Japan, driven in part by expensive new drugs, is now attracting attention at the highest political levels, with a key prime ministerial council set to debate potential cost-cutting measures.
You may also be interested in...
Japan Delays Keytruda Pricing Amid PD-1 Cost Concerns
Regulatory authorities in Japan have put back the granting of a reimbursement price to Keytruda under the national health insurance system amid rising worries over the cost of new cancer immunotherapies, delaying the launch of the product for now.
Ono Files Japan Patent Action As Keytruda Nears Market
Hot on the heels of Keytruda's US approval for first-line use in lung cancer, and just ahead of the drug’s first local launch, rival PD-1 player Ono has launched a patent infringement suit in Japan against Merck, adding to similar actions brought elsewhere by its global Opdivo partner BMS.
Revised Japan Prices Include Big Cuts For Gilead HCV Drugs
With policy surrounding the regular drug price revision in Japan next month finalized and a list of new tariff prices just released, it has become clear that Gilead is facing sizeable reimbursement reductions for its two big-selling hepatitis C drugs in the country.